Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Neeson

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Blood|September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaSimon J Harrison, Hang Quach, Emma Link, et al.
International Immunology|February 6, 2014
B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21Magdalena Hagn, Sue E Blackwell, Thamara Beyer, et al.
Immunotherapy|June 4, 2013
Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptorMelissa A Henderson, Carmen S M Yong, Connie P M Duong, et al.
Cancer Research|November 25, 2010
Tumor ablation by gene-modified T cells in the absence of autoimmunityLeanne X J Wang, Jennifer A Westwood, Maria Moeller, et al.
Immunology and Cell Biology|May 9, 2018
LMP2 immunoproteasome promotes lymphocyte survival by degrading apoptotic BH3-only proteinsDamien Zanker, Kenneth Pang, Sara Oveissi, et al.
Contemporary Clinical Trials Communications|January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocolDavid Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
JAMA Oncology|August 29, 2021
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical TrialShankar Siva, Mathias Bressel, Tao Mai, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genesAnna Sofia Trigos, Anupama Pasam, Patricia Banks, et al.
European Urology|April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 TrialsAlexander D Sherry, Van To, Criselle D'souza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen SettingClare Y Slaney, Bianca von Scheidt, Alexander J Davenport, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Blood|September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaSimon J Harrison, Hang Quach, Emma Link, et al.
International Immunology|February 6, 2014
B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21Magdalena Hagn, Sue E Blackwell, Thamara Beyer, et al.
Immunotherapy|June 4, 2013
Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptorMelissa A Henderson, Carmen S M Yong, Connie P M Duong, et al.
Cancer Research|November 25, 2010
Tumor ablation by gene-modified T cells in the absence of autoimmunityLeanne X J Wang, Jennifer A Westwood, Maria Moeller, et al.
Immunology and Cell Biology|May 9, 2018
LMP2 immunoproteasome promotes lymphocyte survival by degrading apoptotic BH3-only proteinsDamien Zanker, Kenneth Pang, Sara Oveissi, et al.
Contemporary Clinical Trials Communications|January 25, 2021
A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocolDavid Pryor, Mathias Bressel, Nathan Lawrentschuk, et al.
JAMA Oncology|August 29, 2021
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical TrialShankar Siva, Mathias Bressel, Tao Mai, et al.
Journal for Immunotherapy of Cancer|June 28, 2022
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genesAnna Sofia Trigos, Anupama Pasam, Patricia Banks, et al.
European Urology|April 28, 2026
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 TrialsAlexander D Sherry, Van To, Criselle D'souza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen SettingClare Y Slaney, Bianca von Scheidt, Alexander J Davenport, et al.
Pageof 4